Barriers to Optimal Disease Control for Rheumatoid Arthritis Patients With Moderate and High Disease Activity
Open Access
- 27 August 2013
- journal article
- research article
- Published by Wiley in Arthritis Care & Research
- Vol. 66 (2), 190-196
- https://doi.org/10.1002/acr.22108
Abstract
Objective To evaluate barriers that prevent rheumatoid arthritis (RA) patients from achieving Disease Activity Score in 28 joints using the erythrocyte sedimentation rate (DAS28‐ESR) scores within the current recommended levels for low disease activity (LDA) or clinical remission (DAS28‐ESR score <3.2). Methods Using an electronic medical record program, clinical data for RA patients treated in Optimising Patient Outcomes in Australian Rheumatology clinics, with a recorded DAS28‐ESR score, were collected at one point in time. The data included demographics, medications, disease measures, and the rheumatologist's opinion of the main barriers preventing improvement to the recommended DAS28 score. Results Of the 4,037 patients with a recorded DAS28‐ESR score, 304 patients (7.5%) had high disease activity (HDA) and 1,211 patients (30%) had moderate disease activity (MDA). For 584 HDA or MDA patients, the barriers to disease control (BTCs) were recorded by the rheumatologist when there was no adjustment to disease‐modifying antirheumatic drug (DMARD) therapy. The recorded BTCs were irreversible joint damage (19.7%), patient‐driven preference (14.7%), noninflammatory musculoskeletal pain (9.2%), insufficient time to assess the effect of recently initiated DMARDs (9.2%), safety concerns (7.5%), comorbidities (6.5%), resistant disease (6.3%), and other less common reasons. These patients received DMARDs (97.4%), including biologic agents (34.1%), methotrexate (74.8%), and oral corticosteroids (41.8%). Conclusion This study identified clinical situations in which rheumatologists elected to continue RA patients with MDA or HDA on DMARD therapy without adjustment to achieve clinical remission or an LDA target of a DAS28‐ESR score <3.2.This publication has 17 references indexed in Scilit:
- 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritisArthritis Care & Research, 2012
- Merging Veterans Affairs rheumatoid arthritis registry and pharmacy data to assess methotrexate adherence and disease activity in clinical practiceArthritis Care & Research, 2011
- Patient‐physician discordance in assessments of global disease severity in rheumatoid arthritisArthritis Care & Research, 2010
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugsAnnals Of The Rheumatic Diseases, 2010
- Treating rheumatoid arthritis to target: recommendations of an international task forceAnnals Of The Rheumatic Diseases, 2010
- Factors that influence rheumatologists' decisions to escalate care in rheumatoid arthritis: Results from a choice-based conjoint analysisArthritis Care & Research, 2010
- Resistance of rheumatoid arthritis patients to changing therapy: Discordance between disease activity and patients' treatment choicesArthritis & Rheumatism, 2007
- Principles of assessment from a clinical perspectiveBest Practice & Research Clinical Rheumatology, 2003
- Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritisArthritis & Rheumatism, 1995